Related Experiment Video
Updated: Jun 12, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Characterization of Anti-Canine PD-1 Antibodies
Colin J Hartman1, Petra Sergent1, Anna Barbara Emilia Zimmermann2,3
1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH 03756, USA.
New canine cancer immunotherapies show promise. Anti-canine PD-1 antibodies were engineered and tested, demonstrating safety and tumor control in a small study, offering hope for better canine cancer treatments.
Area of Science:
- Veterinary Oncology
- Immunotherapy
- Canine Cancer Research
Background:
- Canine cancer is a significant cause of death, with limited therapeutic options.
- Human cancer therapies like immune checkpoint inhibitors have transformed treatment outcomes.
- Exploring similar immunotherapeutic strategies for dogs could improve clinical benefits.
Purpose of the Study:
- To engineer and characterize mouse and chimeric mouse-canine anti-canine PD-1 (cPD-1) monoclonal antibodies.
- To evaluate the safety and efficacy of these antibodies in canine cancer patients.
- To assess the potential of anti-cPD-1 antibodies as a novel immunotherapeutic approach for dogs.
Main Methods:
- Development of monoclonal antibodies targeting canine PD-1 (cPD-1).
- Functional characterization of antibody-mediated blockade of the cPD-1/cPD-L1 immune signaling pathway.
- Proof-of-concept intratumoral therapy in seven companion canine cancer patients using HugPetmab.
Main Results:
- Engineered anti-cPD-1 antibodies successfully blocked the cPD-1/cPD-L1 interaction.
- Intratumoral therapy with HugPetmab was safe and well-tolerated in canine patients.
- Evidence of tumor control was observed in a subset of treated tumors.
Conclusions:
- Anti-cPD-1 antibodies hold potential as a novel immunotherapeutic strategy for canine cancer.
- HugPetmab demonstrated safety and preliminary efficacy, supporting its further development.
- This research paves the way for expanded immunotherapeutic options in veterinary oncology.
More Related Videos
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
Related Concept Videos
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...